RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
Portfolio Pulse from
Johnson & Johnson announced that its combination therapy of RYBREVANT® and LAZCLUZE™ significantly outperforms the standard of care in treating EGFR-mutated lung cancer, with a projected median overall survival improvement exceeding one year. The data will be presented at the 2025 European Lung Cancer Congress.
March 20, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's new data shows its combination therapy for EGFR-mutated lung cancer significantly outperforms the current standard, potentially boosting its oncology portfolio and stock price.
The announcement of significant improvement in overall survival for a major cancer treatment can positively impact JNJ's stock price. The data presented at a major congress highlights the potential market impact and strengthens JNJ's oncology portfolio.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100